Neuro Immunoassay Market Set To Grow From $3.12 Billion In 2026 To $4.28 Billion By 2030 At A CAGR Of 8.2%
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Neuro Immunoassay Market Size Outlook: How Fast Will Revenue Grow Through 2030?
The neuro immunoassay (NIA) market size has experienced significant expansion in recent years. It is anticipated to increase from $2.88 billion in 2025 to $3.12 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.5%. The historical growth of this market can be attributed to the escalating demand for sensitive neurological diagnostics, the increased integration of immunoassay techniques in neuroscience research, the rising incidence of neurodegenerative disorders, the expansion of clinical and research laboratories, and an intensified focus on early disease detection and monitoring.
The neuro immunoassay (NIA) market is projected to experience substantial expansion in the coming years, reaching $4.28 billion by 2030, driven by a compound annual growth rate (CAGR) of 8.2%. This growth during the forecast period is attributable to several factors, including the increasing integration of neuro immunoassay (NIA) with artificial intelligence (AI) for data analysis, rising investments in biomarker discovery, wider adoption of personalized medicine and therapeutic monitoring, the expansion of high-throughput screening platforms, and an increasing demand for automated and precise immunoassay systems. Key trends anticipated over the forecast period encompass technology-driven innovations enhancing assay sensitivity and specificity, progress in artificial intelligence (AI)-enabled data interpretation, the evolution of multiplexed and lab-on-a-chip immunoassay systems, intensified research and development efforts in identifying neuro biomarkers, and novel integrated and automated neurodiagnostic platforms.
Download A Free Sample Report For Comprehensive Market Insights:
Neuro Immunoassay Market Opportunity Drivers: What Is Creating New Revenue Potential?
The escalating occurrence of neurological disorders is anticipated to propel the future growth of the neuro immunoassay market. Neurological disorders are medical conditions that impact the brain, spinal cord, and nerves, thereby disrupting normal nervous system function and resulting in impairments concerning movement, cognition, sensation, behavior, or overall bodily control. The increasing prevalence of these disorders arises from unhealthy lifestyle habits, such as poor diet, physical inactivity, smoking, excessive alcohol consumption, and chronic stress. Neuro immunoassays assist in detecting specific biomarkers within the nervous system, facilitating early diagnosis and targeted treatment for neurological patients. For instance, in April 2024, according to the National Institutes of Health (NIH), a US-based government agency, an estimated 6.9 million Americans aged 65 and older are currently living with Alzheimer’s dementia, and this figure is projected to nearly double to 13.8 million by 2060. Consequently, the rising prevalence of neurological disorders drives the neuro immunoassay market.
Neuro Immunoassay Market Segment Outlook: Which Categories Are Expanding The Fastest?
The neuro immunoassay market covered in this report is segmented –
1) By Product Type: Reagents And Kits, Analyzers
2) By Technology: Radioimmunoassays (RIA), Polymerase Chain Reaction (PCR), Enzyme-Linked Immunosorbent Assay (ELISA), Western Blot, Rapid Tests, Enzyme-Linked Immunospot Assay (ELISPOT)
3) By Analyte Or Biomarker Type: Amyloid-Beta (Aß), Tau Protein (p-Tau), Alpha-Synuclein (a-syn), Neurofilament Light Chain (NfL), Autoantibodies, Cytokines, Glial Fibrillary Acidic Protein (GFAP), Neuron-Specific Enolase (NSE), Ubiquitin C-Terminal Hydrolase L1 (UCH-L1), Brain-Derived Neurotrophic Factor (BDNF)
4) By Application: Alzheimer’s Disease, Parkinson’s Disease (PD), Huntington’s Disease, Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA)
5) By End-User: Hospitals, Clinics, Academic Organizations, Biopharmaceutical Companies, Pharmaceutical Companies, Other End-Users
Subsegments:
1) By Reagents And Kits: Enzyme Linked Immunosorbent Assay Reagents, Western Blotting Kits, Multiplex Assay Kits
2) By Analyzers: Automated Immunoassay Analysers, Point Of Care Immunoassay Analysers, High Throughput Immunoassay Analysers
Neuro Immunoassay Market Innovation Trends Driving Future Development
Leading firms within the neuro immunoassay market are concentrating on creating sophisticated solutions, including blood-based neurological biomarker assays, to improve the tracking of diseases, elevate prognostic precision, and assist clinical choices for neurological conditions. These blood-based assays are tests designed to quantify particular proteins, like Neurofilament Light Chain (NfL), found in human serum or plasma, with the goal of evaluating neuronal damage and the level of disease activity. An illustrative instance occurred in June 2024, when Siemens Healthineers, an in vitro diagnostics company based in Germany, obtained CE marking for its Neurofilament Light Chain blood test, intended for deployment on the Atellica IM Analyzer and ADVIA Centaur systems. This particular test measures NfL levels to assist in foreseeing the risk of neuronal injury in adults experiencing relapsing multiple sclerosis, serving as an addition to existing clinical, imaging, and laboratory evaluations. The CE mark signifies adherence to European In Vitro Diagnostic Regulations, thereby broadening the availability of standardized neuro immunoassay diagnostics across laboratories throughout Europe.
Neuro Immunoassay Market Key Companies And Competitive Benchmarking
Major companies operating in the neuro immunoassay market are Thermo Fisher Scientific Inc., Merck KGaA, Bio-Rad Laboratories Inc., GenScript Biotech Corporation, Abcam plc, BioLegend Inc., Meso Scale Diagnostics LLC, Sino Biological Inc., Quanterix Corporation, Cusabio Technology LLC, OriGene Technologies Inc., Elabscience Biotechnology Inc., RayBiotech Life Inc., Enzo Life Sciences Inc., Rockland Immunochemicals Inc., Assay Genie Ltd., Novus Biologicals LLC, Creative Diagnostics, MyBioSource Inc., Immuno-Biological Laboratories Co. Ltd., Boster Biological Technology, Cloud-Clone Corp., FineTest Biotech Inc., Abbexa Ltd.
Access The Complete Neuro Immunoassay Market Report:
Neuro Immunoassay Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the neuro immunoassay (NIA) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuro immunoassay market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
